This web site is not optimized for Internet Explorer 6. You may notice
decreased functionality compared to other web browsers. Please follow the
link below to upgrade to a new version of Internet Explorer.

The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 
Peripheral Drug Eluting Stents

XIENCE PRIME Everolimus Eluting Stent System, BTK

Indications & Important Safety Information ››
 

 

Overview

xience

The Next Step in BTK Efficacy

 

Introducing XIENCE PRIME Everolimus Eluting Stent System, now indicated for severe claudication and critical limb ischemia in infrapopliteal lesions. Clinically proven for primary stenting of focal lesions, XIENCE PRIME is engineered for outstanding performance.

 

 

 

 

XIENCE PRIME is built on XIENCE V DES technology

 

Specifications

The Next Step in BTK Efficacy - Excellent Long-Term Patency

Clinically proven for Primary stenting of focal lesions

XP BTK Patency Chart

 

 

In the DESTINY trial, the DES BTK intervention demonstrated excellent long-term patency (angiographic binary in-stent restenosis (>50% stenosis)) of 85.2% and 98.7% limb salvage at 1 year.1,2

 

 

 

 

 

Excellent long-term patency

 

Engineered for outstanding performance

XP BTK

 

Leading MULTI-LINK Stent Design

Exceptional acute performance, uncompromised radial force and visibility

XP BTK

 

Innovative Delivery System

Excellent deliverability and confident deployment

XP BTK

 

Everolimus

Efficacious low-dose potent anti-proliferative drug

XP BTK

 

Coating Technology

Superb integrity for reliable expansion and controlled drug release

 

Longest DES Available for BTK


With lengths up to 38mm, XIENCE PRIME is the longest DES indicated for BTK procedures

 

1.DESTINY is a multi-center, randomized Investigator Sponsored Study designed to evaluate safety and efficacy of XIENCE V vs MULTI-LINK VISION in CLI lesions (Rutherford 4, 5) on 140 patients.
2. M. Bosiers, VEITH 2010
3. M. Bosiers, CIRSE 2010

 

Ordering Information

International XIENCE PRIME product numbers

Stent Length (mm)
Stent Diameter (mm)
8
12
15
18
23
28 33 38
2.25
1011706-08
1011706-12
1011706-15
1011706-18
1011706-23
1011706-28 - -
2.50
1011707-08
1011707-12
1011707-15
1011707-18
1011707-23 1011707-28 1011707-33 1011707-38
2.75
1011708-08
1011708-12
1011708-15
1011708-18
1011708-23 1011708-28 1011708-33 1011708-38
3.00
1011709-08
1011709-12 1011709-15
1011709-18
1011709-23 1011709-28 1011709-33 1011709-38
3.50
1011710-08
1011710-12
1011710-15
1011710-18
1011710-23 1011710-28 1011711-33 1011710-38
4.00
1011711-08
1011711-12
1011711-15
1011711-18
1011711-23 1011711-28 1011711-33 1011711-38
 
  XIENCE PRIME SV XIENCE PRIME XIENCE PRIME LL  

AP2933693 Rev. B

 

Indications and Important Safety Information

Top

Top